Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

BioMedPartners AG. (2/16/17). "Press Release: BioMedPartners Raise CHF 75 Million in First Closing of Their New Healthcare Venture Fund". Basel.

Organisations Organisation BioMedInvest III fund
  Group BioMedPartners (Group)
  Organisation 2 European Investment Fund (EIF)
  Group EU (govt)
Products Product BioMedInvest III fund
Index term Index term BioMedPartners–SEVERAL: investment, 201702 first closing CHF75m of BioMedInvest III fund incl cornerstone investor EIF + Berner Kantonalbank
Persons Person Hosang, Markus (BioMedPartners 201108 General Partner)
  Person 2 Wallnöfer, Andreas (Jeito Capital 202202– Partner Investor before BioMedPartners + Roche)

BioMedPartners today announced the first closing of BioMedInvest III, their third equity venture capital fund, at CHF 75 million.

BioMedInvest III is a healthcare venture capital fund which invests in private early-to-midstage companies in Switzerland, Germany and neighboring countries of the European Union.

“We are delighted that the continued success of BioMedInvest convinced many of the major investors of the previous funds to commit also to BioMedInvest III. Among these are the European Investment Fund (EIF) on behalf of the ERP-EIF Dachfonds as cornerstone investor, and the Berner Kantonalbank, BEKB. In addition we could gain several important new private investors.” says Dr. Markus Hosang, General Partner at BioMedPartners.

“We are proud of having been able to establish BioMedPartners as a leading venture group over the last ten years. Taking into consideration the challenging venture capital market environment in Europe, this is a major milestone for the future of the Swiss Life Science Cluster”, adds Thomas Moeller, General Partner at BioMedPartners.

“The expertise and successful investment track record that the BioMedPartners team brings to the table will enable it to translate innovative science into new companies, products and economic benefit and future growth. Most importantly, these investments will provide novel and effective therapies to patients in need.” says Dr. Andreas Wallnöfer, previous Head of Clinical Research & Exploratory Development at F. Hoffmann- La- Roche AG, who joins BioMedPartners as a Partner.

The BioMedPartners team includes experienced R&D and venture capital professionals, and has access to an extensive network of industry experts and scientific leaders. The new fund will continue BioMedPartners’ successful strategy of investing in innovative biopharmaceutical, medical device and diagnostics companies that have a strong science and technology base, an innovative product portfolio addressing unmet medical needs, a competent leadership and a promising business perspective.

With a target size of CHF 120-150 million, BioMedInvest III will invest in 12 – 16 private companies, supporting them not only by providing funds, but also by having members of its strong management team taking board responsibility in its portfolio companies, and by providing access to its extensive network of industry experts and scientific leaders.

The fund will start to invest immediately, and the final closing is foreseen for early 2018.

About BioMedPartners

Based in Basel, BioMedPartners is a leading independent European venture capital firm, providing private equity to early- to mid-stage life sciences companies, frequently acting as lead- or co-lead investor. Since 2003, BioMedPartners has invested in more than 50 highly innovative companies, of which 17 have already either successfully been acquired by leading biopharma players (e.g. ESBATech AG, GlycArt Biotechnology AG, Okairos AG and SuppreMol GmbH) or have completed an IPO (e.g. Affimed AG, Curetis AG and Santhera Pharmaceuticals AG). With more than CHF 320 million in capital under management and a strong team of experienced industry experts as well as an extensive scientific network, BioMedPartners has established itself as one of the leading early-stage human healthcare investors in Europe.


Dr. Markus Hosang
General Partner BioMedPartners

Thomas Möller
General Partner BioMedPartners

Stefan Fäs
Partner / CFO BioMedPartners

Dr. Andreas Wallnöfer
Partner BioMedPartners

Disclaimer This press release appears as a matter of record only and shall not constitute an offer, solicitation or recommendation in relation to any securities, investment products or investment services in any jurisdiction where it is unlawful to do so.

Record changed: 2023-06-05


Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for BioMedPartners (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Healthtech Company Mika 650x300px

» top